Literature DB >> 34636639

PET of Fibroblast-Activation Protein for Breast Cancer Diagnosis and Staging.

David A Mankoff1, Mark A Sellmyer1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34636639      PMCID: PMC8717688          DOI: 10.1148/radiol.2021212098

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


× No keyword cloud information.
  10 in total

1.  Fibroblast activation protein, a dual specificity serine protease expressed in reactive human tumor stromal fibroblasts.

Authors:  J E Park; M C Lenter; R N Zimmermann; P Garin-Chesa; L J Old; W J Rettig
Journal:  J Biol Chem       Date:  1999-12-17       Impact factor: 5.157

Review 2.  The Future of Nuclear Medicine, Molecular Imaging, and Theranostics.

Authors:  Wolfgang A Weber; Johannes Czernin; Carolyn J Anderson; Ramsey D Badawi; Henryk Barthel; Frank Bengel; Lisa Bodei; Irène Buvat; Marcelo DiCarli; Michael M Graham; Jan Grimm; Ken Herrmann; Lale Kostakoglu; Jason S Lewis; David A Mankoff; Todd E Peterson; Heinrich Schelbert; Heiko Schöder; Barry A Siegel; H William Strauss
Journal:  J Nucl Med       Date:  2020-12       Impact factor: 10.057

3.  Comparison of 18F-FDG PET/CT for Systemic Staging of Newly Diagnosed Invasive Lobular Carcinoma Versus Invasive Ductal Carcinoma.

Authors:  Molly P Hogan; Debra A Goldman; Brittany Dashevsky; Christopher C Riedl; Mithat Gönen; Joseph R Osborne; Maxine Jochelson; Clifford Hudis; Monica Morrow; Gary A Ulaner
Journal:  J Nucl Med       Date:  2015-08-20       Impact factor: 10.057

4.  68Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer.

Authors:  Clemens Kratochwil; Paul Flechsig; Thomas Lindner; Labidi Abderrahim; Annette Altmann; Walter Mier; Sebastian Adeberg; Hendrik Rathke; Manuel Röhrich; Hauke Winter; Peter K Plinkert; Frederik Marme; Matthias Lang; Hans-Ulrich Kauczor; Dirk Jäger; Jürgen Debus; Uwe Haberkorn; Frederik L Giesel
Journal:  J Nucl Med       Date:  2019-04-06       Impact factor: 10.057

5.  Simultaneous FAPI PET/MRI Targeting the Fibroblast-Activation Protein for Breast Cancer.

Authors:  Philipp Backhaus; Matthias C Burg; Wolfgang Roll; Florian Büther; Hans-Jörg Breyholz; Stefanie Weigel; Walter Heindel; Michaela Pixberg; Peter Barth; Joke Tio; Michael Schäfers
Journal:  Radiology       Date:  2021-10-12       Impact factor: 11.105

Review 6.  Tumor-specific positron emission tomography imaging in patients: [18F] fluorodeoxyglucose and beyond.

Authors:  David A Mankoff; Janet F Eary; Jeanne M Link; Mark Muzi; Joseph G Rajendran; Alexander M Spence; Kenneth A Krohn
Journal:  Clin Cancer Res       Date:  2007-06-15       Impact factor: 12.531

Review 7.  ¹⁸F-FDG PET/CT for Staging and Restaging of Breast Cancer.

Authors:  David Groheux; Alexandre Cochet; Olivier Humbert; Jean-Louis Alberini; Elif Hindié; David Mankoff
Journal:  J Nucl Med       Date:  2016-02       Impact factor: 10.057

Review 8.  Hallmarks of cancer: the next generation.

Authors:  Douglas Hanahan; Robert A Weinberg
Journal:  Cell       Date:  2011-03-04       Impact factor: 41.582

Review 9.  Therapeutic Targeting of the Tumor Microenvironment.

Authors:  Leire Bejarano; Marta J C Jordāo; Johanna A Joyce
Journal:  Cancer Discov       Date:  2021-04       Impact factor: 39.397

10.  FAPI-74 PET/CT Using Either 18F-AlF or Cold-Kit 68Ga Labeling: Biodistribution, Radiation Dosimetry, and Tumor Delineation in Lung Cancer Patients.

Authors:  Frederik L Giesel; Sebastian Adeberg; Mustafa Syed; Thomas Lindner; Luis David Jiménez-Franco; Eleni Mavriopoulou; Fabian Staudinger; Eric Tonndorf-Martini; Sebastian Regnery; Stefan Rieken; Rami El Shafie; Manuel Röhrich; Paul Flechsig; Andreas Kluge; Annette Altmann; Jürgen Debus; Uwe Haberkorn; Clemens Kratochwil
Journal:  J Nucl Med       Date:  2020-06-26       Impact factor: 10.057

  10 in total
  1 in total

Review 1.  Clinical summary of fibroblast activation protein inhibitor-based radiopharmaceuticals: cancer and beyond.

Authors:  Mengting Li; Muhsin H Younis; Yongxue Zhang; Weibo Cai; Xiaoli Lan
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-01-31       Impact factor: 10.057

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.